Monitor the company's next 6-K for actual net proceeds and use of proceeds disclosure. The 180-day lock-up and no-VRT restriction limit near-term secondary issuance risk, but the dilutive structure and lack of specific use of proceeds beyond working capital suggest the company is in need of cash. Watch for any subsequent filings indicating the company's cash runway or operational updates.
Price Chart
Executive Summary
Basel Medical Group Ltd is raising up to $6.0 million through a registered direct offering of units, each consisting of one ordinary share (or pre-funded warrant) and one common warrant with a 5-year term. The offering is priced at $1.33 per unit, with common warrants exercisable at $1.463 (110% of the offering price). The company has engaged Cathay Securities as placement agent and is subject to a 180-day lock-up and no-Variable-Rate-Transaction restriction. This is a dilutive capital raise with no stated use of proceeds beyond working capital.
Key Facts
- Up to $6.0 million in units being sold at $1.33 per unit
- Each unit: 1 ordinary share (or pre-funded warrant) + 1 common warrant (5-yr term, exercise price $1.463)
- Common warrants have a zero-cash exercise option and a price floor of $1.463
- Placement agent: Cathay Securities, receiving 6.0% cash fee plus up to $60,000 expense reimbursement
- 180-day lock-up on insiders and prohibition on Variable Rate Transactions
- Registration statement (F-1) effective September 29, 2026
- Proceeds for working capital purposes only
Financial Impact
Up to $6.0 million gross proceeds; dilution from up to 4.5M shares (assuming full exercise of common warrants at $1.463) plus pre-funded warrants
Risk Factors
- Dilution from up to $6.0M in new shares and warrants
- No specific use of proceeds beyond working capital — suggests cash need
- Common warrants exercisable at 110% of offering price — may not be exercised if stock trades below $1.463
- Pre-funded warrants effectively already paid for — immediate dilution upon exercise
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-046409 |
| Exhibit: ex4-1.htm | 0001493152-26-046409 |
| Exhibit: ex4-2.htm | 0001493152-26-046409 |
| Exhibit: ex4-3.htm | 0001493152-26-046409 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 6-K | $3.85 $3.85 | · 0.00% | ▼ −1.08% | $4.55 (−18.18%) |
Oct 9, 2026 17d ago | 6-K | $3.75 $3.71 | ▲ +1.07% | ▲ +1.01% | $4.55 (−21.33%) |
Oct 8, 2026 18d ago | 424B4 | $3.75 $3.71 | ▲ +1.07% | ▲ +1.01% | $4.55 (−21.33%) |
Sep 30, 2026 26d ago | EFFECT | $3.12 $3.02 | ▼ −3.21% | ▼ −3.38% | $4.55 (+45.83%) |
Sep 2, 2026 7w ago | 6-K | $4.94 $4.78 | ▼ −3.24% | ▼ −4.29% | $4.55 (−7.89%) |
Aug 10, 2026 11w ago | 6-K | $4.90 $4.99 | ▼ −1.84% | ▼ −2.16% | $4.55 (+7.14%) |
Jul 10, 2026 15w ago | 6-K | $6.61 $6.14 | ▼ −7.04% | ▼ −6.27% | $4.55 (−31.11%) |
Jun 10, 2026 19w ago | 6-K | $0.5869 $0.5783 | ▼ −1.47% | ▼ −3.17% | $4.55 (+675.26%) |
Jun 5, 2026 20w ago | 6-K | $0.5445 $0.5946 | ▲ +9.20% | ▲ +8.97% | $4.55 (+735.63%) |
Mar 30, 2026 30w ago | 6-K | $6.60 $7.08 | ▲ +7.27% | ▲ +4.37% | $4.55 (−31.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers